Navigation Links
ADA Informs Patients About Osteoporosis Medications and Oral Health
Date:3/9/2009

ADA creates brochures with National Osteoporosis Foundation

CHICAGO, March 9 /PRNewswire-USNewswire/ -- Dental patients who have been alarmed or confused by recent news reports about how osteoporosis medications might affect their oral health now have a brochure to help them separate fact from fiction. The American Dental Association (ADA) collaborated with the National Osteoporosis Foundation to create the brochure, "Osteoporosis Medications and Your Dental Health," which will be available in dental offices this month.

The brochure explains that some patients who have taken bisphosphonates, a common class of drugs taken by those with osteoporosis or low-bone density, have developed bisphosphonate-associated osteonecrosis of the jaw. Osteonecrosis of the jaw is a rare but serious condition that can cause severe damage to the jawbone. This condition is diagnosed in patients who have an area of exposed bone in the jaw that persists for more than eight weeks, who have no history of radiation therapy to the head and neck and who are taking, or have taken, a bisphosphonate medication.

The chance of developing osteonecrosis of the jaw for patients who take bisphosphonates is unknown; however researchers agree that the chance appears to be very small. In fact, 94 percent of people diagnosed with osteonecrosis of the jaw are cancer patients who are or have received repeated high doses of bisphosphonates intravenously. The remaining 6 percent diagnosed with osteonecrosis of the jaw took oral bisphosphonates.

"Patients who take bisphosphonates for osteoporosis are encouraged to talk to their dentist so that their dentist can show them good oral hygiene practices as well as monitor their oral health," says Matthew Messina, D.D.S., ADA Consumer Advisor and a general dentist based in Ohio. "Patients should not stop taking their osteoporosis medications without speaking with their physicians."

According to the ADA, the benefits of osteoporosis medications greatly outweigh the risks of developing osteonecrosis of the jaw.

Osteoporosis is a serious condition that causes 2 million bone fractures a year, according to the National Osteoporosis Foundation. Half of women and 20 percent of men older than 50 will break a bone due to osteoporosis. Bisphosphonates are commonly prescribed to prevent broken bones. Common bisphosphonate medications include alendronate (Fosamax(R)), ibandronate (Boniva(R)), risedonate (Actone(R)) and zoledronic acid (Reclast(R)).

The "Osteoporosis Medications and Your Dental Health" brochures will be available in dental offices or for purchase by dentists on the ADA's Web site at www.ada.org. For more information about osteonecrosis of the jaw, please visit the ADA's Web site at http://www.ada.org/prof/resources/topics/osteonecrosis.asp or the National Osteoporosis Foundation's Web site at www.nof.org.

About the American Dental Association

Celebrating its 150th anniversary, the not-for-profit ADA is the nation's largest dental association, representing more than 157,000 dentist members. The premier source of oral health information, the ADA has advocated for the public's health and promoted the art and science of dentistry since 1859. The ADA's state-of-the-art research facilities develop and test dental products and materials that have advanced the practice of dentistry and made the patient experience more positive. The ADA Seal of Acceptance long has been a valuable and respected guide to consumer dental care products. The monthly Journal of the American Dental Association (JADA) is the best-read scientific journal in dentistry. For more information about the ADA, visit the Association's Web site at www.ada.org


'/>"/>
SOURCE American Dental Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. LegalView Informs Readers of New Criminal Probe Involving Peanut Butter Recall Salmonella Poisonings
2. LegalView Informs Parents of Crib Recall Following Several Infant Deaths Caused by Asphyxiation from Improper Crib Mechanisms
3. LegalView Informs Chantix Patients of Risk of Seizures Leading to Traffic Accidents
4. LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis
5. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
6. Math battling cancer, deciding lifes challenges lead list as INFORMS meet in Seattle
7. Nasdaq Informs Synutra that the Companys Filing Delinquency has been Cured
8. Ecstasy could help patients with post-traumatic stress disorder
9. Diabetes and Elevated Levels of Cholesterol Linked to Faster Cognitive Decline in Alzheimer's Patients
10. New DNA Test Is Basis for Groundbreaking IVF Refund Plan, Easing Financial Burden for Patients
11. Saving heart attack patients in the middle of the night
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... It has just been announced ... for five events throughout the month of May. , Uldrich is the author of ... outlets. He also frequently appears on the Science Channel’s FutureScape and Discovery Channel’s Inside ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... Issue 1 of Patient Experience Journal (PXJ), an international, open access, peer-reviewed ... With almost half the issue representing international (non-US) based authors, the third volume ...
(Date:5/2/2016)... ... 02, 2016 , ... Beanfields, PBC, makers of Beanfields Bean ... students at University of Colorado in Boulder to create new advertising campaigns. , ... the School of Journalism, who selected Beanfields as the brand on which to ...
(Date:5/2/2016)... ... 2016 , ... Amica Life Insurance Company has unveiled ... various life stages. , The site launched on April 1, and it has ... to the times when life insurance matters most. , “Through our research, we ...
(Date:5/2/2016)... ... 2016 , ... The National Resident Matching Program® (NRMP®) has ... Match”), the system through which U.S. and international medical school students and graduates ... placed in the 2016 Match, and 29,572 were filled when the matching algorithm ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... -- TapImmune,Inc. (TPIV), a clinical-stage immune-oncology ... immunotherapeutics and vaccines for the treatment of cancer & metastatic ... Annual Growth Capital Expo to be held on May ... Palace in Las Vegas, Nevada.  The Company presentation will ... by Dr. John N. Bonfiglio a TapImmune ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
(Date:4/27/2016)... -- Elekta today announced that its leading-edge ... focal point of seven scientific presentations at ESTRO 35, ... & Oncology, taking place April 29 - May 3. ... and a high-field MRI scanner with sophisticated software that ... in real time. The MR-linac is designed to improve ...
Breaking Medicine Technology: